After tumultuous year, Zymeworks delivers ‘unequivocal, unprecedented’ pivotal data, boosting shares 30%
“Very clear, unequivocal and unprecedented” is how Zymeworks CEO Kenneth Galbraith heralded results from a mid-phase study of biliary tract cancer drug zanidatamab, which sent shares soaring nearly 30%.